Eric Van Cutsem, MD, discusses a subgroup analysis involving patients 75 years of age and older in the Consign study of regorafenib for treatment-refractory metastatic colorectal cancer. The analysis found no major differences in safety compared with younger patients as long as the patients were fit enough to be eligible for treatment—so age itself is no reason to withhold regorafenib.
Device has shelf life of 12 to 18 months
Institutions overlook simple precautions
Glecaprevir/pibrentasvir combo achieves high virologic response rates
ITI-007 is equivalent to placebo
Pivotal study meets all secondary endpoints
More than 3,000 cases reported in continental U.S.
Lumacaftor/ivacaftor combination previously approved for patients 12 years of age and older
“Artificial pancreas” adjusts insulin levels
Treatment reduces monthly migraine days
Organisms shed essential cell-wall molecules
P&T September 2016
Table of Contents
Regorafenib Safe for Older Colorectal Cancer Patients
ESMO World Congress on Gastrointestinal Cancer, June 29–July 2, 2016